Login to Your Account

Eisai: FDA Action Is Robbing Belviq of Exclusivity

By Mari Serebrov
Washington Editor

Monday, August 12, 2013
The FDA jumped the gun on clocking the five-year exclusivity of Belviq from the date it granted approval – a move that would rob the obesity drug of nearly a year of exclusivity, Eisai Inc. claimed in a recent citizen petition that asks the agency to reset the clock.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription